iSpecimen Inc.
iSpecimen Inc. scores highest on Earnings (40) and lowest on Nitro (3). Its PosiPenta is 24.36 out of 100, weaker than most similar companies.
On the Penta Grid this week, iSpecimen Inc. is Grid #814 of 837 in the Healthcare sector in United States, and Grid #3,839 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| iSpecimen Inc. | 24.36 | 36 | 40 | 3 | 25 | 18 |
| BioRestorative Therapies, Inc. | 33.95 | 43 | 31 | 10 | 44 | 41 |
| Revelation Biosciences, Inc. | 44.03 | 97 | 48 | 9 | 37 | 29 |
| Nexalin Technology, Inc. | 31.03 | 32 | 30 | 9 | 50 | 34 |
| Lunai Bioworks Inc. | 41.40 | 0 | 48 | 6 | 94 | 58 |
| Onconetix, Inc. | 43.54 | 99 | 53 | 1 | 50 | 14 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.02 |
| P/B ratio | 1.33 |
EEarnings
| Trailing EPS | ₹-5018.00 |
| Forward EPS | ₹-74.82 |
NNitro
| Price | 86.85 |
| 52-week high | 3440.05 |
| 52-week low | 86.20 |
| Fall from 52-week high | 97.5% |
TTorque
| Return on equity (ROE) | -968.47% |
| Debt-to-equity | 0.14 |
AAnchor
| Beta (price swings) | 1.65 |
| Market cap | ₹21 Cr |
| Insider holding | 0.00% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is iSpecimen Inc.'s PosiPenta score?
iSpecimen Inc.'s PosiPenta is 24.36 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does iSpecimen Inc. stand on the Penta Grid?
On the Penta Grid this week, iSpecimen Inc. is Grid #814 of 837 in the Healthcare sector in United States, and Grid #3,839 of 4,000 in United States.
Which PosiPenta pillar is strongest for iSpecimen Inc.?
Earnings (growth), with a score of 40 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for iSpecimen Inc.?
Nitro (momentum), with a score of 3 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.